Amgen appointed James Bradner executive vice president of R&D, and chief scientific officer, and David Reese executive vice president and chief technology officer. Bradner and Reese will report to Robert Bradway, Chairman and CEO at Amgen. Bradner will be responsible for advancing Amgen’s pipeline, which includes potential first-in-class medicines in all stages of development and across the company’s four therapeutic areas of focus: oncology, inflammation, general medicine, an...